Skip to main content
. 2020 Feb 4;12(2):357. doi: 10.3390/cancers12020357

Figure 1.

Figure 1

Inhibitors have been designed to target major pathways deregulated in acute myeloid leukemia (Bcl-2), mutant form of metabolic regulatory enzymes (IDH1/2), and proliferation (FLT3). Abbreviations: 2-HG: 2-hydroxyglutarate; α-KG: Alpha-ketoglutarate; BAX: Bcl-2-like protein 4; Bim: Bcl-2-like protein 11; Bcl-2: B-cell lymphoma 2; FLT3: Fms-related tyrosine kinase 3; IDH: Isocitrate dehydrogenase; ITD: Internal tandem duplication; NADP(H): Nicotinamide adenine dinucleotide phosphate; TKD: Tyrosine kinase domain.